

## Disclaimer

- This presentation has been prepared by Duni AB (the "Company") solely for use at this investor presentation and is furnished to you solely for your information and may not be reproduced or redistributed, in whole or in part, to any other person. By attending the meeting where this presentation is made, or by reading the presentation slides, you agree to be bound by the following limitations.
- This presentation is not for presentation or transmission into the United States or to any U.S. person, as that term is defined under Regulation S promulgated under the Securities Act of 1933, as amended.
- This presentation contains various forward-looking statements that reflect management's current views with respect to future events and financial and operational performance. The words "believe," "expect," "anticipate," "intend," "may," "plan," "estimate," "should," "could," "aim," "target," "might," or, in each case, their negative, or similar expressions identify certain of these forward-looking statements. Others can be identified from the context in which the statements are made. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which are in some cases beyond the Company's control and may cause actual results or performance to differ materially from those expressed or implied from such forward-looking statements. These risks include but are not limited to the Company's ability to operate profitably, maintain its competitive position, to promote and improve its reputation and the awareness of the brands in its portfolio, to successfully operate its growth strategy and the impact of changes in pricing policies, political and regulatory developments in the markets in which the Company operates, and other risks.
- The information and opinions contained in this document are provided as at the date of this presentation and are subject to change without notice.
- No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, the fairness, accuracy or completeness of the information contained herein. Accordingly, none of the Company, or any of its principal shareholders or subsidiary undertakings or any of such person's officers or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.


## 2011 Q3 Highlights

- Net sales declined by 2,8\% to SEK 917 m (943) ${ }^{1)}$
- Underlying operating income amounted to SEK $98 \mathrm{~m}(103)^{11}$ 2)
- Underlying operating margin amounted to 10.7\% $(11,0 \%)^{1)}$ 2)
- Stable development within Professional
- South \& East growing parallel with stability in mature markets.
- Price increases to compensate for high raw material costs gradually implemented.
- Seasonally weak quarter for Retail
- Fully impact from the phase out of a major private label customer.
- Maintaining or improving market shares in weak grocery retail environment.
- Strong third quarter for Tissue, mainly derived from improved productivity and capacity utilization

1) Excluding translation effect: net sales SEK 928 m , underlying operating income SEK 97 m with underlying operating margin $10,4 \%$
2) Excluding market valuation of derivatives SEK $0 \mathrm{~m}(-1)$ and restructuring costs of SEK 0 m (0)


## Market Outlook

- HORECA market long-term growing in line or slightly above GDP
- Positive eating out trend.
- Higher growth in take-away sector.
- Retail growth in line with GDP over time
- Continuous weak retail markets in Western Europe, albeit improving compared to last year.
- Even though private-label over-represented in category, competitive pressure remains fierce.
- Shift in economic growth perspectives and consumer confidence due to debt and Euro crisis
- Consumer's confidence starts to weaken.
- HORECA market statistics still positive but distributors somewhat more cautious.
- Production input material as well as traded goods remain on historical high levels
- Some signs that peak have been reached.
- Price increases to customers gradually implemented with full effect in fourth quarter.



# HORECA Sales Development, Germany (Q2 2011) 

Umsatzentwicklung im Gastgewerbe 2. Quartal 2011 und 1. Halbjahr 2011
(Veränderungen gegenüber Vorjahreszeitraum)

| Betriebsart | 2. Quartal 2011 |  | 1. Halbjahr 2011 |  |
| :--- | :---: | :---: | :---: | :---: |
|  | nominal | real | nominal | real |
| Hotellerie (Hotels, Hotels garnis, <br> Gasthöfe, Pensionen) | $4,7 \%$ | $4,0 \%$ | $4,8 \%$ | $4,2 \%$ |
| Beherbergungsgewerbe insge- <br> samt | $\mathbf{4 , 4 \%}$ | $3,7 \%$ | $\mathbf{4 , 5} \%$ | $3,7 \%$ |
| Speisengeprägte <br> Gastronomie | $4,0 \%$ | $2,6 \%$ | $4,2 \%$ | $2,8 \%$ |
| Getränkegeprăgte <br> Gastronomie | $1,1 \%$ | $0,3 \%$ | $1,9 \%$ | $1,0 \%$ |
| Gaststättengewerbe <br> insgesamt | $3,7 \%$ | $2,2 \%$ | $4,0 \%$ | $2,6 \%$ |
| Event-Caterer | $0,1 \%$ | k.A. | $2,0 \%$ | k.A. |
| Erbringung sonstiger Verpfle- <br> gungsdienstleistungen | $2,8 \%$ | k.A. | $2,7 \%$ | k.A. |
| Caterer und sonstige Verpfle- <br> gungsdienstleistungen | $2,5 \%$ | $\mathbf{1 , 1 \%}$ | $2,7 \%$ | $1,2 \%$ |
| Gastgewerbe insgesamt | $3,8 \%$ | $2,6 \%$ | $\mathbf{4 , 0} \%$ | $2,9 \%$ |

## Restaurant Sales Development, Sweden (July 2010 - July 2011)



- $-0,3 \%$ in volume in July and $+3,2 \%$ in value.
- $+4,8 \%$ in volume YTD and $+7,8 \%$ in value



## Professional - Stability



## Geographical split - sales Q3 2011

| Net sales Professional | Q3 2011 | Q3 2010 | Growth | Growth at fixed exchange rates |
| :---: | :---: | :---: | :---: | :---: |
| Nordic | 152 | 152 | 0.0\% | 0.0\% |
| Central Europe | 417 | 412 | 1.2\% | 2.9\% |
| South \& East Europe | 119 | 111 | 7.2\% | 9.9\% |
| Rest of the World | 8 | 6 | 33.3\% | 33.3\% |
| TOTAL | 696 | 681 | 2.2\% | 3.7\% |
| - EBIT margin burdened by sales and marketing investments. |  |  |  |  |

[^0]
## Retail - Seasonally weak quarter

## Sales and EBIT ${ }^{1}$



## Geographical split - sales Q3 2011

| Net sales <br> Retail | Q3 2011 | Q3 2010 | GrowthGrowth at <br> fixed <br> exchange <br> rates |  |
| :--- | ---: | ---: | ---: | ---: |
| Nordic | 16 | 18 | $-11.1 \%$ | $-11.1 \%$ |
| Central <br> Europe | 90 | 108 | $-16.7 \%$ | $-15.7 \%$ |
| South \& East <br> Europe | 4 | 12 | $-66.7 \%$ | $-66.7 \%$ |
| Rest of the <br> World | 0 | 0 | $0.0 \%$ | $0.0 \%$ |
| TOTAL | $\mathbf{1 1 0}$ | $\mathbf{1 3 8}$ | $\mathbf{- 2 0 . 3 \%}$ | $\mathbf{- 1 9 . 6 \%}$ |

- Full impact from phase out of major private label customer across most regions.

1) Excluding non-recurring costs and market valuation of derivatives

## Tissue - Improved production efficiency

Sales and EBIT


Sales mix Q3 2011


- Balance between internal and external volumes enables more stable capacity utilization.
- Successful work with continues improvement.

26/10/11


## Income Statement

| SEKm | Q3 | Q3 | YTD | YTD | LTM | $\begin{array}{r} \text { FY } \\ 2010 \end{array}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 011 | 2010 | 2011 | 2010 |  |  |
| Net sales | 917 | 943 | 2744 | 2873 | 3842 | 3971 |
| Gross profit | 248 | 245 | 716 | 739 | 1028 | 1052 |
| Gross margin | 27.1\% | 26.0\% | 26.1\% | 25.7\% | 26.8\% | 26.5\% |
| Selling expenses | -105 | -99 | -332 | -328 | -439 | -434 |
| Administrative expenses | -43 | -43 | -128 | -129 | -173 | -174 |
| R\&D expenses | -7 | -5 | -21 | -16 | -29 | -25 |
| Other operating net | 4 | 4 | 9 | 0 | 26 | 17 |
| Operating income (reported) | 98 | 102 | 244 | 267 | 413 | 436 |
| Non-recurring items ${ }^{1)}$ | 0 | -1 | -9 | -5 | -2 | 1 |
| Operating income (underlying) | 98 | 103 | 253 | 272 | 416 | 435 |
| Operating margin (underlying) | 10.7\% | 11.0\% | 9.2\% | 9.5\% | 10.8\% | 10.9\% |
| Financial net | -8 | -3 | -20 | -12 | -26 | -18 |
| Taxes | -26 | -27 | -61 | -66 | -107 | -112 |
| Net income | 63 | 72 | 163 | 189 | 280 | 306 |
| Earnings per share | 1.34 | 1.54 | 3.46 | 4.02 | 5.96 | 6.52 |

1) Restructuring costs and market valuation of derivatives
$12 \quad 26 / 10 / 11$

## Improved Efficiency in Tissue

| SEKm |  | Q3 | Q3 | YTD | YTD | LTM | $\begin{array}{r} \text { FY } \\ 2010 \end{array}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | 2011 | 2010 | 2011 | 2010 |  |  |
| Professional | Net sales | 696 | 681 | 2016 | 2025 | 2774 | 2783 |
|  | Operating income ${ }^{1)}$ | 93 | 97 | 237 | 260 | 361 | 384 |
|  | Operating margin | 13.3\% | 14.3\% | 11.7\% | 12.8\% | 13.0\% | 13.8\% |
| Retail | Net sales | 110 | 138 | 403 | 458 | 634 | 689 |
|  | Operating income ${ }^{1)}$ | -5 | -1 | -3 | -1 | 29 | 32 |
|  | Operating margin | -4.4\% | -1.0\% | -0.8\% | -0.2\% | 4.6\% | 4.6\% |
| Tissue | Net sales | 111 | 124 | 324 | 390 | 433 | 499 |
|  | Operating income ${ }^{1)}$ | 10 | 7 | 20 | 13 | 26 | 18 |
|  | Operating margin | 9.2\% | 5.8\% | 6.1\% | 3.2\% | 5.9\% | 3.7\% |
| Duni | Net sales | 917 | 943 | 2744 | 2873 | 3842 | 3971 |
|  | Operating income ${ }^{1)}$ | 98 | 103 | 253 | 272 | 416 | 435 |
|  | Operating margin | 10.7\% | 11.0\% | 9.2\% | 9.5\% | 10.8\% | 10.9\% |

1) Excluding non-recurring cost and market valuation of derivates

13 26/10/11

# Improved Cash Flow driven by Working Capital Reduction 

| SEKm | Q3 Q3 |  | YTD | YTD | LTM | FY |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2011 | 2010 | 2011 | 2010 |  | 2010 |
| EBITDA ${ }^{1)}$ | 125 | 130 | 333 | 351 | 520 | 537 |
| Capital expenditure | -58 | -45 | -177 | -178 | -236 | -236 |
| Change in; Inventory | -66 | -66 | -92 | -150 | -25 | -83 |
| Accounts receivable | 38 | 17 | -23 | -41 | -57 | -74 |
| Accounts payable | 4 | -1 | -4 | -41 | 45 | 7 |
| Other operating working capital | 26 | -24 | 46 | -20 | 40 | -26 |
| Change in working capital | 3 | -74 | -74 | -252 | 3 | -175 |
| Operating cash flow | 70 | 11 | 83 | -79 | 287 | 126 |

1) Excluding non-recurring costs and market valuation of derivatives
$14 \quad 26 / 10 / 11$

## Financial Position Remains Solid

| Km 03 2011 03 2010 FY 2010 |  |  |  |
| :---: | :---: | :---: | :---: |
| Goodwill | 1199 | 1199 | 1199 |
| Tangible and intangible fixed assets | 728 | 603 | 632 |
| Net financial assets ${ }^{1{ }^{1}}$ | 241 | 290 | 253 |
| Inventories | 534 | 506 | 437 |
| Accounts receivable | 670 | 610 | 634 |
| Accounts payable | -315 | -270 | -315 |
| Other operating assets and liabilities ${ }^{3}$ | -323 | -278 | -266 |
| Net assets | 2734 | 2658 | 2573 |
| Net debt | 755 | 785 | 582 |
| Equity | 1979 | 1872 | 1991 |
| Equity and net debt | 2734 | 2658 | 2573 |
| ROCE ${ }^{2}$ | 17\% | 19\% | 19\% |
| ROCE ${ }^{2}$ ) w/o Goodwill | 32\% | 38\% | 40\% |
| Net debt / Equity | 38\% | 42\% | 29\% |
| Net debt / EBITDA ${ }^{2}$ | 1.5 | 1.4 | 1.1 |

1) Deferred tax assets and liabilities + Income tax receivables and payables
2) Excluding non-recurring costs and market valuation of derivatives
3) Including restructuring provision and derivatives
$15 \quad 26 / 10 / 11$

- Organic growth of 5\% over a business cycle
- Consider acquisitions to reach new markets or to strengthen current market positions

EBIT margin $>10 \%$

- Top line growth - premium focus
- Improvements in manufacturing, sourcing and logistics


## Dividend payout

 ratio 40+\%- Target at least $40 \%$ of net profit

3:50 SEK per share (2010)


[^0]:    1) Excluding non-recurring costs and market valuation of derivatives
    $8 \quad 26 / 10 / 11$
